HeyJaredFrederik Joelving
- Indexed articles, last 90 days
- 8
- Latest publication
- Sep 30, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 20, 2026
Latest articles
Nearly 1 in 8 Cancers Worldwide Caused by Infections (opens the original)
Read excerpt
About 2.3 million cancer diagnoses in 2024, or 12% of all cases globally, were caused by infections, according to a new study from the Interna ti onal Agency for Research on Cancer (IARC). Those cancers were attributable to 12 infectious agents known to be carcinogenic to humans. At the top of list were Helicobacter pylori and human papillomavirus (HPV), which together caused roughly 1.5 million cancers worldwide in 2024. H. pylori is the primary cause of gastric cancers globally, while certain
Hot Drinks Tied to Esophageal Cancer. Should Patients Worry? (opens the original)
Read excerpt
Drinking very hot beverages was associated with a threefold higher risk of developing esophageal squamous cell carcinoma (ESCC) than consuming warm beverages, suggested a large new study from the UK that has been making headlines across the globe. If the link is causal, consuming beverages “hot” instead of “very hot” could prevent an estimated 14% of new ESCC cases, or 440 cancers each year in the UK, researchers reported. The study of nearly 1 million people is consistent with previous research
First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC (opens the original)
Read excerpt
First-line trastuzumab deruxtecan (T-DXd; ENHERTU) improves progression-free survival compared with standard chemoimmunotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to new phase 3 data. Among over 400 patients in the DESTINY-Lung04 trial, T-DXd achieved an “unprecedented” median progression-free survival of 14.3 months vs 8.3 months with pembrolizumab plus platinum-based chemotherapy. This is the first phase 3 trial to show benefit fro
Brain MRI Surveillance Alone May Be Enough in SCLC (opens the original)
Read excerpt
Skipping prophylactic cranial radiotherapy cuts the risk for cognitive failure or death in patients with small-cell lung cancer (SCLC) who are receiving brain MRI surveillance, according to results from the MAVERICK phase 3 clinical trial. The study, of over 300 patients with limited-stage or extensive-stage SCLC, found that MRI surveillance alone reduced the risk for cognitive failure or death by 40% vs MRI surveillance plus prophylactic cranial irradiation (PCI). Patients who skipped radiother
Stroke Risk Peaks in the 3 Months After Cancer Diagnosis (opens the original)
Read excerpt
The first 3 months after cancer diagnosis is a critical period for stroke risk, and patients with lung or pancreatic cancers are most vulnerable, a nationwide study from Israel finds. Among over 180,000 patients with a first cancer diagnosis, the risk of ischemic stroke peaked during the first 3 months post-diagnosis, at an incidence rate 2.5 times that of the general population. Patients with lung or pancreatic cancer faced the highest risks during that early period and for the first year after
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.